104 related articles for article (PubMed ID: 12850790)
1. Suicide genes as safety switches in T lymphocytes.
Straathof KC; Spencer DM; Sutton RE; Rooney CM
Cytotherapy; 2003; 5(3):227-30. PubMed ID: 12850790
[TBL] [Abstract][Full Text] [Related]
2. Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma.
Cooper LJ; Ausubel L; Gutierrez M; Stephan S; Shakeley R; Olivares S; Serrano LM; Burton L; Jensen MC; Forman SJ; DiGiusto DL
Cytotherapy; 2006; 8(2):105-17. PubMed ID: 16698684
[TBL] [Abstract][Full Text] [Related]
3. The CD20/alphaCD20 'suicide' system: novel vectors with improved safety and expression profiles and efficient elimination of CD20-transgenic T cells.
van Meerten T; Claessen MJ; Hagenbeek A; Ebeling SB
Gene Ther; 2006 May; 13(9):789-97. PubMed ID: 16421601
[TBL] [Abstract][Full Text] [Related]
4. Multi-cistronic vector encoding optimized safety switch for adoptive therapy with T-cell receptor-modified T cells.
van Loenen MM; de Boer R; Hagedoorn RS; Jankipersadsing V; Amir AL; Falkenburg JH; Heemskerk MH
Gene Ther; 2013 Aug; 20(8):861-7. PubMed ID: 23364317
[TBL] [Abstract][Full Text] [Related]
5. Modulation of GvHD by suicide-gene transduced donor T lymphocytes: clinical applications in mismatched transplantation.
Ciceri F; Bonini C; Gallo-Stampino C; Bordignon C
Cytotherapy; 2005; 7(2):144-9. PubMed ID: 16040393
[TBL] [Abstract][Full Text] [Related]
6. A novel 'sort-suicide' fusion gene vector for T cell manipulation.
Fehse B; Kustikova OS; Li Z; Wahlers A; Bohn W; Beyer WR; Chalmers D; Tiberghien P; Kühlcke K; Zander AR; Baum C
Gene Ther; 2002 Dec; 9(23):1633-8. PubMed ID: 12424616
[TBL] [Abstract][Full Text] [Related]
7. Escherichia coli-nitroreductase suicide gene control of human telomerase reverse transcriptase-transduced minor histocompatibility antigen-specific cytotoxic T cells.
Verdijk RM; Wilke M; Beslier V; Kloosterman A; Brand A; Goulmy E; Mutis T
Bone Marrow Transplant; 2004 May; 33(9):963-7. PubMed ID: 15048139
[TBL] [Abstract][Full Text] [Related]
8. Immune selection and emergence of aggressive tumor variants as negative consequences of Fas-mediated cytotoxicity and altered IFN-gamma-regulated gene expression.
Liu K; Caldwell SA; Abrams SI
Cancer Res; 2005 May; 65(10):4376-88. PubMed ID: 15899830
[TBL] [Abstract][Full Text] [Related]
9. Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells.
Marin V; Cribioli E; Philip B; Tettamanti S; Pizzitola I; Biondi A; Biagi E; Pule M
Hum Gene Ther Methods; 2012 Dec; 23(6):376-86. PubMed ID: 23186165
[TBL] [Abstract][Full Text] [Related]
10. Gene therapy to improve function of T cells for adoptive immunotherapy.
Quintarelli C; Savoldo B; Dotti G
Methods Mol Biol; 2010; 651():119-30. PubMed ID: 20686964
[TBL] [Abstract][Full Text] [Related]
11. Retroviral vector insertions in T-lymphocytes used for suicide gene therapy occur in gene groups with specific molecular functions.
Giordano FA; Fehse B; Hotz-Wagenblatt A; Jonnakuty S; del Val C; Appelt JU; Nagy KZ; Kuehlcke K; Naundorf S; Zander AR; Zeller WJ; Ho AD; Fruehauf S; Laufs S
Bone Marrow Transplant; 2006 Aug; 38(3):229-35. PubMed ID: 16785865
[TBL] [Abstract][Full Text] [Related]
12. Potent tumor-specific immunity induced by an in vivo heat shock protein-suicide gene-based tumor vaccine.
Ren W; Strube R; Zhang X; Chen SY; Huang XF
Cancer Res; 2004 Sep; 64(18):6645-51. PubMed ID: 15374979
[TBL] [Abstract][Full Text] [Related]
13. Synergy of adoptive T-cell therapy and intratumoral suicide gene therapy is mediated by host NK cells.
Sanchez-Perez L; Gough M; Qiao J; Thanarajasingam U; Kottke T; Ahmed A; Thompson JM; Maria Diaz R; Vile RG
Gene Ther; 2007 Jul; 14(13):998-1009. PubMed ID: 17443216
[TBL] [Abstract][Full Text] [Related]
14. Gene transfer for activation of CMV specific T cells.
André-Schmutz I; Dal Cortivo L; Hamel Y; Cavazzana-Calvo M
Hum Immunol; 2004 May; 65(5):565-70. PubMed ID: 15172458
[TBL] [Abstract][Full Text] [Related]
15. GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia.
Turin I; Pedrazzoli P; Tullio C; Montini E; La Grotteria MC; Schiavo R; Perotti C; Locatelli F; Carretto E; Maccario R; Siena S; Montagna D
Cytotherapy; 2007; 9(5):499-507. PubMed ID: 17786611
[TBL] [Abstract][Full Text] [Related]
16. Clinical-grade preparation of human natural regulatory T-cells encoding the thymidine kinase suicide gene as a safety gene.
Guillot-Delost M; Cheraï M; Hamel Y; Rosenzwajg M; Baillou C; Simonin G; Leclercq V; Mariotti-Ferrandiz ME; Six A; Bon-Durand V; Maury S; Salomon BL; Cohen JL; Klatzmann D; Lemoine FM
J Gene Med; 2008 Aug; 10(8):834-46. PubMed ID: 18615770
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of murine prostate cancer using whole tumor cells killed ex vivo by herpes simplex viral thymidine kinase/ganciclovir suicide gene therapy.
Pandha H; Eaton J; Greenhalgh R; Soars D; Dalgleish A
Cancer Gene Ther; 2005 Jun; 12(6):572-8. PubMed ID: 15803141
[TBL] [Abstract][Full Text] [Related]
18. Adoptive immuno-gene therapy of cancer with single chain antibody [scFv(Ig)] gene modified T lymphocytes.
Lamers CH; Sleijfer S; Willemsen RA; Debets R; Kruit WH; Gratama JW; Stoter G
J Biol Regul Homeost Agents; 2004; 18(2):134-40. PubMed ID: 15471217
[TBL] [Abstract][Full Text] [Related]
19. Cancer-specific targeting of an adenovirus-delivered herpes simplex virus thymidine kinase suicide gene using translational control.
Mathis JM; Williams BJ; Sibley DA; Carroll JL; Li J; Odaka Y; Barlow S; Nathan CO; Li BD; DeBenedetti A
J Gene Med; 2006 Sep; 8(9):1105-20. PubMed ID: 16802401
[TBL] [Abstract][Full Text] [Related]
20. Combine cancer gene therapy harnessing plasmids expressing human tumor necrosis factor alpha and Herpes simplex thymidine kinase suicide gene.
Pastorakova A; Hlubinova K; Jakubikova J; Altaner C
Neoplasma; 2006; 53(5):353-62. PubMed ID: 17013529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
